07:00 , Oct 17, 2016 |  BC Week In Review  |  Company News

Trinity diagnostic news

Trinity withdrew its 510(k) submission and will begin a strategic review to determine the best use of its Meritas Troponin-I test technology. The company withdrew the application after FDA raised concerns over the device’s operating...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Clinical News

Meritas Troponin I test regulatory update

Trinity said its Meritas Troponin I point-of-care test received CE Mark approval as an aid in diagnosing myocardial infarction (MI) in the emergency room. The company immediately launched the fluorescence immunoassay for in vitro quantitative...
07:00 , Mar 12, 2012 |  BC Week In Review  |  Company News

Fiomi Diagnostics AB, Trinity deal

Trinity acquired fellow point-of-care diagnostic company Fiomi from its founders and private equity groups Alfven & Didrikson Invest AB and Nexttobe AB in a cash and stock deal valued at $9.7 million. Fiomi is eligible...
07:00 , Jun 23, 2008 |  BC Week In Review  |  Company News

Amic, J&J deal

Johnson & Johnson acquired Amic for an undisclosed amount. J&J said the acquisition complements the clinical laboratory, immunohematology and donor screening businesses of its Ortho-Clinical Diagnostic Inc. subsidiary. Amic’s technology uses a chip-based microfluidic platform...
08:00 , Jan 7, 2008 |  BC Week In Review  |  Company News

Amic, Roche sales and marketing update

Amic received a non-exclusive license from Roche 's Roche Diagnostics unit to market an NT-proBNP POC test for cardiovascular indications in Europe. The test will be launched on Amic's Forecast POC diagnostic system. Amic AB...